In publicly available databases (proteinatlas.org) the expression of SATB1, TBB5 and VIME is stated as being moderate to weak in prostate cancer and for SPIN1 and TPM4 as strong to weak depending on the antibody used31. This evidence concerns the gene TPM4 and prostate carcinoma.